“We are exceptionally proud to see that Enterome, a company we developed from the very first steps, has become a successful business, a potential leader in the field of immunomodulation for oncology, as well as immune and autoimmune diseases,” commented Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners.
“I’m delighted that a prominent company such as Nestlé Health Science recognises Enterome as an important player by entering into such a high-profile collaboration agreement. Immunomodulation, leveraging the microbiome for food allergies, has a great promise for the future of medicine.”
The Health for Life Capital fund, managed by Seventure, has been the largest investor in Enterome, and supported the development of the company from inception.
With the two Health for Life Capital funds (€160 and €250 million) and coinvestments funds, Seventure is worldwide leader in microbiome investments with renowned portfolio companies.
The funds attract strategic investments from prestigious organisations including Danone, Novartis, US-based global food ingredient providers, Lesaffre, Tornier, Tereos, Unigrains and Bel, as well as financial institutions, family offices and entrepreneurs.